Form 4: Bicara Therapeutics COO Sells Shares Under 10b5-1 Plan

Bicara Therapeutics President and COO Ryan Cohlhepp reported exercising stock options and selling common stock totaling 49,600 shares under a Rule 10b5-1 plan.

Summary

• Ryan Cohlhepp, President and COO, and Director of Bicara Therapeutics Inc. (BCAX), reported transactions involving common stock and stock options.
• All reported transactions occurred on October 6, 2025, and October 7, 2025, and were executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.
• On October 6, 2025, Cohlhepp exercised options to acquire 24,000 shares of common stock at an exercise price of $3.7898 per share.
• On October 6, 2025, Cohlhepp sold a total of 39,600 shares of common stock at a weighted average price of $18.0555 per share, with individual sales ranging from $18.00 to $18.22.
• On October 7, 2025, Cohlhepp exercised options to acquire 8,000 shares of common stock at an exercise price of $3.7898 per share.
• On October 7, 2025, Cohlhepp sold a total of 10,900 shares of common stock at a weighted average price of $18.0591 per share, with individual sales ranging from $18.00 to $18.18.
• Following these reported transactions, Cohlhepp beneficially owns 202,641 shares of common stock and 165,334 stock options.

Sentiment

Score: 5

Explanation: The filing reports pre-scheduled insider transactions (option exercises and subsequent sales) under a Rule 10b5-1 plan, which are generally considered neutral events as they are not indicative of new, material information about the company's prospects.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating planned and not opportunistic selling, which enhances transparency.
• The reporting person realized a significant profit by exercising options at $3.7898 and selling shares at weighted average prices around $18.05.

Negatives

• A high-ranking officer and director sold a significant number of shares (49,600 shares in total), which some investors might perceive as a negative signal, despite the pre-planned nature.

Future Outlook

NA

Industry Context

NA

Corporate Governance

Stakeholder Impact

• Shareholders: May view the insider selling as a neutral event due to the pre-planned nature under a Rule 10b5-1 plan, or potentially a slight negative if they interpret it as a lack of conviction, despite the pre-planning.

Key Dates

Recommendation

The filing details pre-scheduled insider transactions under a Rule 10b5-1 plan, which are typically not considered a strong signal for future stock performance. While a high-ranking officer sold shares, the pre-planned nature mitigates concerns of opportunistic selling. Therefore, the filing itself does not provide sufficient new information to warrant a change in investment recommendation, suggesting a 'hold' position based solely on this report.

Keywords

Bicara Therapeutics, BCAX, Form 4, insider trading, stock options, share sale, Ryan Cohlhepp, Rule 10b5-1